The maintenance of an Overweight rating and the announcement of a $107 price target by a reputable analyst firm like Cantor Fitzgerald could lead to increased investor confidence in Ultragenyx Pharmaceutical. This positive analyst outlook is likely to contribute to a bullish sentiment in the short term, potentially driving the stock price up.